{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T17:43:54Z","timestamp":1789753434211,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T00:00:00Z","timestamp":1643587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"national natural science foundation of china","doi-asserted-by":"publisher","award":["31870758"],"award-info":[{"award-number":["31870758"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007225","name":"ministry of science and technology","doi-asserted-by":"publisher","award":["2016YFE0128500"],"award-info":[{"award-number":["2016YFE0128500"]}],"id":[{"id":"10.13039\/100007225","id-type":"DOI","asserted-by":"publisher"}]},{"name":"jilin provincial science & technology department","award":["20200201025JC"],"award-info":[{"award-number":["20200201025JC"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Triple-receptor negative breast cancer (TNBC) is an aggressive breast tumor subtype that generally has a poor prognosis. This study aimed to investigate the role and regulatory mechanisms of Zinc finger MIZ-type containing 2 (ZMIZ2) in relation to TNBC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Based on data from The Cancer Genome Atlas (TCGA), the expression of ZMIZ2 in different subtypes and its correlation with androgen receptor (AR) were analyzed, and a regulatory mechanism network was constructed. The expression and prognostic value of ZMIZ2 in clinical TNBC tissue samples were also investigated. Furthermore, in vitro studies were conducted to investigate the effects of ZMIZ2 knockdown on the malignant behaviors of TNBC cells and target gene expression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Based on TCGA data, ZMIZ2 was found to be significantly upregulated in TNBC tissues and its expression was negatively correlated with AR expression. Key relationships, such as the ZMIZ2-CCL5, ZMIZ2\/AR-MCM3, ZMIZ2\/AR-E2F4, and the ZMIZ2\/AR-DHX38 were identified, which were enriched in NOD-like receptor signaling pathway\/toll-like receptor signaling pathway, DNA replication, cell cycle, and spliceosome, respectively. Moreover, ZMIZ2 was upregulated in clinical breast cancer tissues and its high expression was correlated with the poor prognosis of TNBC patients. Furthermore, ZMIZ2 expression was increased in breast cancer cells, and a knockdown of ZMIZ2 inhibited MDA-MB-231 cell proliferation, migration, and invasion, induced cell cycle arrest in the G1 phase, and promoted cell apoptosis. Furthermore, ZMIZ2 knockdown inhibited the mRNA and protein expression of CCL5, MCM3, E2F4, and DHX38.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings reveal that ZMIZ2 is upregulated in TNBC tissues and is associated with its poor prognosis. ZMIZ2 may promote TNBC progression by promoting the expression of its target genes and affecting the corresponding pathways. Consequently, ZMIZ2 may serve as a promising target for future TNBC treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12935-021-02393-x","type":"journal-article","created":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T11:17:57Z","timestamp":1643627877000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["ZMIZ2 promotes the development of triple-receptor negative breast cancer"],"prefix":"10.1186","volume":"22","author":[{"given":"Xiaopan","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobumoto","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0876-4366","authenticated-orcid":false,"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,31]]},"reference":[{"key":"2393_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.3322\/caac.21601","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020;70:145\u201364.","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2393_CR2","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1002\/cncr.23243","volume":"112","author":"M Brown","year":"2008","unstructured":"Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: The California Cancer Registry, 1999\u20132004. Cancer. 2008;112(4):737\u201347.","journal-title":"Cancer"},{"issue":"15","key":"2393_CR3","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429\u201334.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2393_CR4","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.3390\/cancers12102758","volume":"12","author":"M Oshi","year":"2020","unstructured":"Oshi M, Newman S, Murthy V, Tokumaru Y, Yan L, Matsuyama R, Endo I, Takabe K. ITPKC as a prognostic and predictive biomarker of neoadjuvant chemotherapy for triple negative breast cancer. Cancers. 2020;12(10):2758.","journal-title":"Cancers"},{"issue":"2","key":"2393_CR5","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1158\/2159-8290.CD-18-1177","volume":"9","author":"AC Garrido-Castro","year":"2019","unstructured":"Garrido-Castro AC, Lin NU, Polyak K. Insights into molecular classifications of triple-negative breast cancer: improving patient selection for treatment. Cancer Discov. 2019;9(2):176\u201398.","journal-title":"Cancer Discov"},{"issue":"50","key":"2393_CR6","doi-asserted-by":"publisher","first-page":"35913","DOI":"10.1074\/jbc.M113.529727","volume":"288","author":"SH Lee","year":"2013","unstructured":"Lee SH, Zhu C, Peng Y, Johnson DT, Lehmann L, Sun Z. Identification of a novel role of ZMIZ2 protein in regulating the activity of the Wnt\/\u03b2-catenin signaling pathway. J Biol Chem. 2013;288(50):35913\u201324.","journal-title":"J Biol Chem"},{"issue":"1","key":"2393_CR7","doi-asserted-by":"publisher","first-page":"04017","DOI":"10.1621\/nrs.04017","volume":"4","author":"J Beliakoff","year":"2006","unstructured":"Beliakoff J, Sun Z. Zimp7 and Zimp10, two novel PIAS-like proteins, function as androgen receptor coregulators. Nucl Recep Signal. 2006;4(1):04017.","journal-title":"Nucl Recep Signal"},{"issue":"22","key":"2393_CR8","doi-asserted-by":"publisher","first-page":"6101","DOI":"10.1093\/emboj\/cdg585","volume":"22","author":"M Sharma","year":"2003","unstructured":"Sharma M, Li X, Wang Y, Zarnegar M, Huang CY, Palvimo JJ, Lim B, Sun Z. hZimp10 is an androgen receptor co-activator and forms a complex with SUMO-1 at replication foci. EMBO J. 2003;22(22):6101\u201314.","journal-title":"EMBO J"},{"key":"2393_CR9","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ctrv.2018.06.005","volume":"68","author":"L Gerratana","year":"2018","unstructured":"Gerratana L, Basile D, Buono G, De Placido S, Giuliano M, Minichillo S, Coinu A, Martorana F, De Santo I, Del Mastro L. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102\u201310.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"2393_CR10","doi-asserted-by":"publisher","first-page":"R7","DOI":"10.1186\/bcr3599","volume":"16","author":"DR Cochrane","year":"2014","unstructured":"Cochrane DR, Bernales S, Jacobsen BM, Cittelly DM, Howe EN, D\u2019Amato NC, Spoelstra NS, Edgerton SM, Jean A, Guerrero J. Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide. Breast Cancer Res. 2014;16(1):R7.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2393_CR11","first-page":"353","volume":"4","author":"D Safarpour","year":"2014","unstructured":"Safarpour D, Pakneshan S, Tavassoli FA. Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified? Am J Cancer Res. 2014;4(4):353.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"2393_CR12","doi-asserted-by":"publisher","first-page":"7401","DOI":"10.1007\/s10586-017-1576-y","volume":"22","author":"W Feng","year":"2019","unstructured":"Feng W, Zhu Q, Zhuang J, Yu S. An expert recommendation algorithm based on Pearson correlation coefficient and FP-growth. Clust Comput. 2019;22(3):7401\u201312.","journal-title":"Clust Comput"},{"issue":"7","key":"2393_CR13","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47\u2013e47.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2393_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1093\/nar\/gkg034","volume":"31","author":"CV Mering","year":"2003","unstructured":"Mering CV, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B. STRING: a database of predicted functional associations between proteins. Nucleic Acids Res. 2003;31(1):258\u201361.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"2393_CR15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.gpb.2013.05.001","volume":"11","author":"H Qu","year":"2013","unstructured":"Qu H, Fang X. A brief review on the human encyclopedia of DNA elements (ENCODE) project. Genomics Proteomics Bioinformat. 2013;11(3):135\u201341.","journal-title":"Genomics Proteomics Bioinformat"},{"issue":"23","key":"2393_CR16","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1093\/bioinformatics\/btm369","volume":"23","author":"A Subramanian","year":"2007","unstructured":"Subramanian A, Kuehn H, Gould J, Tamayo P, Mesirov JP. GSEA-P: a desktop application for Gene Set Enrichment Analysis. Bioinformatics. 2007;23(23):3251\u20133.","journal-title":"Bioinformatics"},{"issue":"4","key":"2393_CR17","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/cancers12040916","volume":"12","author":"E Vagia","year":"2020","unstructured":"Vagia E, Mahalingam D, Cristofanilli M. The landscape of targeted therapies in TNBC. Cancers. 2020;12(4):916.","journal-title":"Cancers"},{"issue":"9","key":"2393_CR18","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/cells8090957","volume":"8","author":"M Nedeljkovi\u0107","year":"2019","unstructured":"Nedeljkovi\u0107 M, Damjanovi\u0107 A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge. Cells. 2019;8(9):957.","journal-title":"Cells"},{"issue":"12","key":"2393_CR19","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1007\/s00018-003-3129-1","volume":"60","author":"D Schmidt","year":"2003","unstructured":"Schmidt D, M\u00fcller S. PIAS\/SUMO: new partners in transcriptional regulation. Cell Mol Life Sci CMLS. 2003;60(12):2561\u201374.","journal-title":"Cell Mol Life Sci CMLS"},{"issue":"10","key":"2393_CR20","doi-asserted-by":"publisher","first-page":"8255","DOI":"10.1074\/jbc.C200001200","volume":"277","author":"T Megidish","year":"2002","unstructured":"Megidish T, Xu JH, Xu CW. Activation of p53 by protein inhibitor of activated Stat1 (PIAS1). J Biol Chem. 2002;277(10):8255\u20139.","journal-title":"J Biol Chem"},{"issue":"12","key":"2393_CR21","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1038\/s41418-018-0103-x","volume":"25","author":"A Di Gennaro","year":"2018","unstructured":"Di Gennaro A, Damiano V, Brisotto G, Armellin M, Perin T, Zucchetto A, Guardascione M, Spaink HP, Doglioni C, Snaar-Jagalska BE. A p53\/miR-30a\/ZEB2 axis controls triple negative breast cancer aggressiveness. Cell Death Differ. 2018;25(12):2165\u201380.","journal-title":"Cell Death Differ"},{"issue":"6","key":"2393_CR22","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","volume":"113","author":"Y Shi","year":"2003","unstructured":"Shi Y, Massagu\u00e9 J. Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus. Cell. 2003;113(6):685\u2013700.","journal-title":"Cell"},{"issue":"5","key":"2393_CR23","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1210\/en.2019-00015","volume":"160","author":"DD Seachrist","year":"2019","unstructured":"Seachrist DD, Keri RA. The activin social network: activin, inhibin, and follistatin in breast development and cancer. Endocrinology. 2019;160(5):1097\u2013110.","journal-title":"Endocrinology"},{"issue":"15","key":"2393_CR24","doi-asserted-by":"publisher","first-page":"11465","DOI":"10.1074\/jbc.M109.079327","volume":"285","author":"Y Peng","year":"2010","unstructured":"Peng Y, Lee J, Zhu C, Sun Z. A novel role for protein inhibitor of activated STAT (PIAS) proteins in modulating the activity of Zimp7, a novel PIAS-like protein, in androgen receptor-mediated transcription. J Biol Chem. 2010;285(15):11465\u201375.","journal-title":"J Biol Chem"},{"issue":"7637","key":"2393_CR25","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer\u2013immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"1","key":"2393_CR26","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.14694\/EdBook_AM.2015.35.e25","volume":"35","author":"ML Disis","year":"2015","unstructured":"Disis ML, Stanton SE. Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book. 2015;35(1):e25\u201330.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"2393_CR27","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-15-0255","volume":"75","author":"MW Teng","year":"2015","unstructured":"Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Can Res. 2015;75(11):2139\u201345.","journal-title":"Can Res"},{"key":"2393_CR28","doi-asserted-by":"publisher","first-page":"327","DOI":"10.3389\/fimmu.2014.00327","volume":"5","author":"M Saxena","year":"2014","unstructured":"Saxena M, Yeretssian G. NOD-like receptors: master regulators of inflammation and cancer. Front Immunol. 2014;5:327.","journal-title":"Front Immunol"},{"issue":"1","key":"2393_CR29","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S2095-4964(16)60231-5","volume":"14","author":"M Yimam","year":"2016","unstructured":"Yimam M, Lee Y-C, Moore B, Jiao P, Hong M, Nam J-B, Kim M-R, Hyun E-J, Chu M, Brownell L. Analgesic and anti-inflammatory effects of UP1304, a botanical composite containing standardized extracts of Curcuma longa and Morus alba. J Integr Med. 2016;14(1):60\u20138.","journal-title":"J Integr Med"},{"issue":"6","key":"2393_CR30","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.3892\/ol.2016.5263","volume":"12","author":"L Peng","year":"2016","unstructured":"Peng L, Hu Y, Chen D, Linghu R, Wang Y, Kou X, Yang J, Jiao S. Ubiquitin specific protease 21 upregulation in breast cancer promotes cell tumorigenic capability and is associated with the NOD-like receptor signaling pathway. Oncol Lett. 2016;12(6):4531\u20137.","journal-title":"Oncol Lett"},{"key":"2393_CR31","doi-asserted-by":"crossref","unstructured":"Johnston DG, Corr SC. Toll-like receptor signalling and the control of intestinal barrier function. In: Toll-like receptors. Springer; 2016. pp. 287\u2013300.","DOI":"10.1007\/978-1-4939-3335-8_18"},{"issue":"2","key":"2393_CR32","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.cyto.2015.08.263","volume":"76","author":"E Palm","year":"2015","unstructured":"Palm E, Demirel I, Bengtsson T, Khalaf H. The role of toll-like and protease-activated receptors in the expression of cytokines by gingival fibroblasts stimulated with the periodontal pathogen Porphyromonas gingivalis. Cytokine. 2015;76(2):424\u201332.","journal-title":"Cytokine"},{"issue":"5","key":"2393_CR33","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1080\/08923973.2020.1797779","volume":"42","author":"S Natarajan","year":"2020","unstructured":"Natarajan S, Ranganathan M. Toll-like receptor (TLR) gene expression and immunostimulatory effect of CpG oligonucleotides in hormone receptor positive cell line T47D and triple negative breast cancer cell line MDA-MB-468. Immunopharmacol Immunotoxicol. 2020;42(5):408\u201315.","journal-title":"Immunopharmacol Immunotoxicol"},{"issue":"9","key":"2393_CR34","doi-asserted-by":"publisher","first-page":"e1177","DOI":"10.1002\/cti2.1177","volume":"9","author":"DJ Zanker","year":"2020","unstructured":"Zanker DJ, Spurling AJ, Brockwell NK, Owen KL, Zakhour JM, Robinson T, Duivenvoorden HM, Hertzog PJ, Mullins SR, Wilkinson RW. Intratumoral administration of the Toll-like receptor 7\/8 agonist 3M\u2013052 enhances interferon-driven tumor immunogenicity and suppresses metastatic spread in preclinical triple-negative breast cancer. Clin Transl Immunol. 2020;9(9):e1177.","journal-title":"Clin Transl Immunol"},{"issue":"2","key":"2393_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/PAI.0000000000000397","volume":"26","author":"LDF Valverde","year":"2018","unstructured":"Valverde LDF, de Freitas RD, Pereira TDA, de Resende MF, Agra IM, dos Santos JN, dos Reis MG, Sales C, Gurgel Rocha CA. MCM3: a novel proliferation marker in oral squamous cell carcinoma. Appl Immunohistochem Mol Morphol. 2018;26(2):120\u20135.","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"2393_CR36","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41417-019-0094-x","volume":"27","author":"Z Gao","year":"2020","unstructured":"Gao Z, Man X, Li Z, Bi J, Liu X, Li Z, Li J, Zhang Z, Kong C. PLK1 promotes proliferation and suppresses apoptosis of renal cell carcinoma cells by phosphorylating MCM3. Cancer Gene Ther. 2020;27(6):412\u201323.","journal-title":"Cancer Gene Ther"},{"key":"2393_CR37","first-page":"1","volume":"249","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, Wang Y, Zhu F, Zhang J, Ma X, Zhang D. Gene expression profiling revealed MCM3 to be a better marker than Ki67 in prognosis of invasive ductal breast carcinoma patients. Clin Exp Med. 2020;249:1\u201311.","journal-title":"Clin Exp Med"},{"issue":"19","key":"2393_CR38","doi-asserted-by":"publisher","first-page":"12370","DOI":"10.1074\/jbc.M114.621532","volume":"290","author":"X Han","year":"2015","unstructured":"Han X, Mayca Pozo F, Wisotsky JN, Wang B, Jacobberger JW, Zhang Y. Phosphorylation of minichromosome maintenance 3 (MCM3) by checkpoint kinase 1 (Chk1) negatively regulates DNA replication and checkpoint activation. J Biol Chem. 2015;290(19):12370\u20138.","journal-title":"J Biol Chem"},{"issue":"1","key":"2393_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02015-4","volume":"40","author":"X Sheng","year":"2021","unstructured":"Sheng X, Dai H, Du Y, Peng J, Sha R, Yang F, Zhou L, Lin Y, Xu S, Wu Y. LncRNA CARMN overexpression promotes prognosis and chemosensitivity of triple negative breast cancer via acting as miR143-3p host gene and inhibiting DNA replication. J Exp Clin Cancer Res. 2021;40(1):1\u201317.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2393_CR40","doi-asserted-by":"publisher","first-page":"3558","DOI":"10.1093\/nar\/gkq1313","volume":"39","author":"BK Lee","year":"2011","unstructured":"Lee BK, Bhinge AA, Iyer VR. Wide-ranging functions of E2F4 in transcriptional activation and repression revealed by genome-wide analysis. Nucleic Acids Res. 2011;39(9):3558\u201373.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"2393_CR41","doi-asserted-by":"publisher","first-page":"017","DOI":"10.1186\/s12885-017-3297-2","volume":"17","author":"KMK Mark","year":"2017","unstructured":"Mark KMK, Varn FS, Ung MH, Qian F, Cheng C. The E2F4 prognostic signature predicts pathological response to neoadjuvant chemotherapy in breast cancer patients. BMC Cancer. 2017;17(1):017\u20133297.","journal-title":"BMC Cancer"},{"issue":"10","key":"2393_CR42","doi-asserted-by":"publisher","first-page":"e1061","DOI":"10.1371\/journal.pone.0001061","volume":"2","author":"CM Conboy","year":"2007","unstructured":"Conboy CM, Spyrou C, Thorne NP, Wade EJ, Barbosa-Morais NL, Wilson MD, Bhattacharjee A, Young RA, Tavar\u00e9 S, Lees JA. Cell cycle genes are the evolutionarily conserved targets of the E2F4 transcription factor. PLoS ONE. 2007;2(10):e1061.","journal-title":"PLoS ONE"},{"issue":"2","key":"2393_CR43","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/jcp.21859","volume":"221","author":"H Garneau","year":"2009","unstructured":"Garneau H, Paquin MC, Carrier JC, Rivard N. E2F4 expression is required for cell cycle progression of normal intestinal crypt cells and colorectal cancer cells. J Cell Physiol. 2009;221(2):350\u20138.","journal-title":"J Cell Physiol"},{"issue":"7","key":"2393_CR44","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1136\/jmedgenet-2014-102316","volume":"51","author":"M Ajmal","year":"2014","unstructured":"Ajmal M, Khan MI, Neveling K, Khan YM, Azam M, Waheed NK, Hamel CP, Ben-Yosef T, Baere ED, Koenekoop RK. A missense mutation in the splicing factor gene DHX38 is associated with early-onset retinitis pigmentosa with macular coloboma. J Med Genet. 2014;51(7):444\u20138.","journal-title":"J Med Genet"},{"issue":"11","key":"2393_CR45","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1167\/iovs.18-23849","volume":"59","author":"Z Latif","year":"2018","unstructured":"Latif Z, Chakchouk I, Schrauwen I, Lee K, Santos-Cortez RLP, Abbe I, Acharya A, Jarral A, Ali I, Ullah E, et al. Confirmation of the role of DHX38 in the etiology of early-onset retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2018;59(11):4552\u20137.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"10","key":"2393_CR46","doi-asserted-by":"publisher","first-page":"4164","DOI":"10.1074\/jbc.M116.762757","volume":"292","author":"JM Fraile","year":"2017","unstructured":"Fraile JM, Manchado E, Lujambio A, Quesada V, Campos-Iglesias D, Webb TR, Lowe SW, L\u00f3pez-Ot\u00edn C, Freije JMP. USP39 deubiquitinase is essential for KRAS oncogene-driven cancer. J Biol Chem. 2017;292(10):4164\u201375.","journal-title":"J Biol Chem"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02393-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02393-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02393-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T08:12:20Z","timestamp":1666599140000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02393-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,31]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2393"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02393-x","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,31]]},"assertion":[{"value":"15 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Jilin Province People's Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed consent was signed by all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"52"}}